Neurocrine Biosciences (NBIX) Other Gross PP&E Adjustments (2016 - 2021)
Historic Other Gross PP&E Adjustments for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to -$97.9 million.
- Neurocrine Biosciences' Other Gross PP&E Adjustments fell 3788.73% to -$97.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was -$97.9 million, marking a year-over-year decrease of 3788.73%. This contributed to the annual value of $3.5 million for FY2020, which is 19166.67% up from last year.
- Per Neurocrine Biosciences' latest filing, its Other Gross PP&E Adjustments stood at -$97.9 million for Q3 2021, which was down 3788.73% from -$100.3 million recorded in Q2 2021.
- In the past 5 years, Neurocrine Biosciences' Other Gross PP&E Adjustments registered a high of $62.1 million during Q4 2018, and its lowest value of -$100.3 million during Q2 2021.
- In the last 5 years, Neurocrine Biosciences' Other Gross PP&E Adjustments had a median value of -$62.0 million in 2019 and averaged -$43.6 million.
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first crashed by 9806.89% in 2019, then surged by 19166.67% in 2020.
- Over the past 5 years, Neurocrine Biosciences' Other Gross PP&E Adjustments (Quarter) stood at $38.4 million in 2017, then surged by 61.86% to $62.1 million in 2018, then plummeted by 98.07% to $1.2 million in 2019, then soared by 191.67% to $3.5 million in 2020, then plummeted by 2897.14% to -$97.9 million in 2021.
- Its last three reported values are -$97.9 million in Q3 2021, -$100.3 million for Q2 2021, and -$97.0 million during Q1 2021.